The Dems are trying to get ahead of it with their congressional hearings blaming Trump for not properly vetting the vax. It’s going to be wild when they suddenly claim that they never promoted it.

https://coronavirus.house.gov/sites/democrats.coronavirus.house.gov/files/2022.08.24%20The%20Trump%20White%20House’s%20Relentless%20Attacks%20on%20FDA’s%20Coronavirus%20Response.pdf at 5-6

Trump Administration Political Appointees Blocked FDA Coronavirus Vaccine EUA Guidance Due to “Objections” Over How It Would Impact the Authorization Timeline Ahead of the Presidential Election

• Dr. Hahn told the Select Subcommittee that FDA sent a draft of its coronavirus vaccine EUA guidance to HHS and the White House in September 2020 for review and approval. The guidance advised vaccine manufacturers that they would need to submit phase three trial data in their EUA applications that included a median follow-up duration of at least two months (60 days) after the completion of the primary vaccination series. By that time, it was clear that the guidance would result in FDA not authorizing a vaccine until after the presidential election.

• According to Dr. Hahn, officials in HHS Secretary Alex Azar’s office expressed concerns about whether it was “appropriate” for FDA’s proposed vaccine EUA guidance to advise manufacturers to submit the amount of surveillance data specified. Beginning around mid-September 2020, Dr. Hahn said FDA had multiple meetings and calls with

Secretary Azar, HHS Chief of Staff Brian Harrison, and HHS Deputy Chief of Staff for Policy Paul Mango—none of whom are doctors or otherwise specialized in immunology or vaccinology—regarding the “timeline” and the “scientific and clinical rationale for the guidance.”

• After FDA’s guidance was sent to the White House for review, Dr. Hahn said “[t]here were objections about it” from Mr. Meadows and other White House officials, including “pushback about the issue of the 60 days” of surveillance data. Dr. Hahn said he “objected” to attempts to change the guidance because “any changes would be obviously reported and would further reduce vaccine confidence.” During a September 23, 2020, press conference, President Trump decried the guidance as “a political move” that “has to be approved by the White House,” which “may or may not approve it. A new email obtained by the Select Subcommittee shows that FDA Center for Biologics Evaluation and Research Director (CBER) Dr. Peter Marks contacted Dr. Hahn on September 29, as the guidance languished at the White House, cautioning: “The ambiguity here is actually creating more problems than a decision one way or the other” on whether the guidance would be approved.

• With its formal vaccine EUA guidance stalled for weeks by the White House, FDA unilaterally released an informal set of briefing materials on October 6, 2020, which included an appendix that summarized advice that the agency provided to industry regarding EUA applications—and which publicly revealed that the agency wanted

two months of surveillance data, despite the ongoing “objections” from the White House. Dr. Hahn told the Select Subcommittee that FDA did not seek approval from HHS or the White House before releasing the informal document, but noted that he “proactively reached out to the White House to let them know that this was going.” Later that day, Dr. Hahn said he was called by Mr. Meadows and was told that FDA’s formal vaccine EUA guidance was now approved.

This report is based on a review of thousands of pages of internal correspondence from Trump White House officials, senior HHS officials, and other internal documents obtained by the Select Subcommittee that have not previously been released, as well as transcribed interviews with senior officials, including former FDA Commissioner Hahn, involved in the federal government’s coronavirus response.